Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2025-02-18 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-end report) for SynAct Pharma AB, covering the period January-December 2024. It contains comprehensive financial statements, including income statements, balance sheets, cash flow analysis, and management commentary (VD-ord). It is a substantive financial report for a period shorter than a full fiscal year (in this case, the year-end report which functions as the final quarterly report), fitting the definition of an Interim/Quarterly Report. Q4 2024
2025-02-18 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the fourth quarter and annual results 2024' and contains comprehensive financial data, including income statements, balance sheets, cash flow reports, and management commentary for the period. It is clearly a quarterly financial report, not an announcement of one, and it contains substantive financial data. Q4 2024
2025-02-18 English
Change in number of shares and votes in SynAct Pharma AB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly announces a change in the total number of shares and votes due to a preferential share issue resolved at an extraordinary general meeting. This directly relates to a change in the company's capital structure or share count. The filing type 'Share Issue/Capital Change' (SHA) is the most appropriate fit for reporting the final resulting share count after a capital event. Although it is a short announcement, the core content is the capital change itself, not just announcing another report, making SHA a better fit than RPA or RNS.
2025-01-31 English
Förändring av antalet aktier och röster i SynAct Pharma AB
Share Issue/Capital Change Classification · 99% confidence The document is a short announcement in Swedish titled "Förändring av antalet aktier och röster i SynAct Pharma AB" (Change in the number of shares and votes in SynAct Pharma AB). It explicitly states that the total number of shares and votes has changed due to a rights issue ('förtrycksemissionen') and provides the new total count as of the last trading day of the month. It concludes with a statement that this information is required to be disclosed under financial instrument trading laws and includes a link to an attached PDF document. Because the document is short (1572 chars) and primarily serves to announce a change in capital structure resulting from a prior corporate action (rights issue), it directly relates to share capital changes. The most fitting category is 'Share Issue/Capital Change' (SHA). Although it is an announcement, the core subject matter is the capital change itself, not just the publication of a report, making SHA more specific than RPA or RNS.
2025-01-31 Swedish
SynAct Pharma AB resolves on a directed share issue to guarantors
Share Issue/Capital Change Classification · 100% confidence The document is a press release from SynAct Pharma AB announcing a 'directed share issue' to guarantors as compensation for a previously completed rights issue. It details the number of shares issued, the subscription price, the impact on share capital, and the rationale for the issuance. While it mentions an attachment at the end, the document itself provides the full details of the corporate action (the share issue), making it a primary announcement of a capital change rather than just a notification of a report's publication. Therefore, it falls under 'Share Issue/Capital Change'.
2025-01-09 English
SynAct Pharma AB beslutar om riktad nyemission av aktier till garantigivare
Share Issue/Capital Change Classification · 100% confidence The document is a press release from SynAct Pharma AB announcing a 'directed new share issue' (riktad nyemission) to guarantors as compensation for their role in a previous rights issue. It details the number of shares, the subscription price, the impact on share capital, and the rationale for the transaction. While it discusses a capital change, it is a formal announcement of a corporate action rather than a standalone regulatory filing or a report itself. According to the 'Menu vs Meal' rule, this is a primary announcement of a corporate event (share issuance), which falls under the 'Share Issue/Capital Change' category.
2025-01-09 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.